MIA ATTIAS: Open Payments
NPI 1780356709 · NAPLES, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$547 in 27 payments from 10 companies in 2025. Trend: 2023 $803 · 2024 $592 · 2025 $547
Food & beverage: $547
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 12 | $213 |
| Amgen Inc. | 3 | $64 |
| Novo Nordisk Inc | 2 | $56 |
| Alnylam Pharmaceuticals Inc. | 2 | $45 |
| PFIZER INC. | 2 | $42 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $37 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $34 |
| Biofrontera Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| CVRx, Inc. | 1 | $18 |
Products named: LEQVIO, REPATHA, Wegovy, ONPATTRO, JARDIANCE, Kerendia, ELIQUIS, AMELUZ.
Industry payments across FL — which companies pay providers there.
